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Abstract  90 
 91 
Background and aims. Intestinal failure (IF) is defined as “the reduction of gut function below the 92 
minimum necessary for the absorption of macronutrients and/or water and electrolytes, such that 93 
intravenous supplementation is required to maintain health and/or growth”. Functionally, it may 94 
be classified as type I acute intestinal failure (AIF), type II prolonged AIF and type III chronic 95 
intestinal failure (CIF) The ESPEN Workshop on IF was held in Bologna, Italy, on 15-16 October 96 
2017 and the aims of this document were to highlight the current state of the art and future 97 
directions for research in IF. 98 
Methods. This paper represents the opinion of experts in the field, based on current evidence. It is 99 
not a formal review, but encompasses the current evidence, with emphasis on epidemiology, 100 
classification, diagnosis and management. 101 
Results. IF is the rarest form of organ failure and can result from a variety of conditions that affect 102 
gastrointestinal anatomy and function adversely. Assessment, diagnosis, and short and long-term 103 
management involves a multidisciplinary team with diverse expertise in the field that aims to 104 
reduce complications, increase life expectancy and improve quality of life in patients. 105 
Conclusions. Both AIF and CIF are relatively rare conditions and most of the published work 106 
presents evidence from small, single-centre studies. Much remains to be investigated to improve 107 
the diagnosis and management of IF and future studies should rely on multidisciplinary, 108 
multicentre and multinational collaborations that gather data from large cohorts of patients. 109 
Emphasis should also be placed on partnership with patients, carers and government agencies in 110 
order to improve the quality of research that focuses on patient-centred outcomes that will help 111 
to improve both outcomes and quality of life in patients with this devastating condition.  112 
 113 
Key words: intestinal failure; short bowel syndrome; definitions; management; acute; chronic;  114 
 115 
116 
4 
 
Contents 117 
1. Introduction 118 
2. Epidemiology of intestinal failure 119 
3. Identification of intestinal failure 120 
4. Multidisciplinary management of intestinal failure 121 
5. Acute intestinal failure 122 
5.1 Assessment of type II prolonged-acute intestinal failure 123 
5.2 Intestinal ischemic injury as a cause of acute intestinal failure 124 
5.3 Nutrition therapy and fluid and electrolyte balance 125 
5.4 Stoma and wound care 126 
5.5 Prevention and management of sepsis 127 
6. Chronic intestinal failure 128 
6.1 Short bowel syndrome: spontaneous and induced post-resection intestinal adaptation 129 
6.2 Short bowel syndrome: enhanced post-resection intestinal adaptation 130 
6.3 Outcome on home parenteral nutrition 131 
6.4 Prevention and treatment of catheter-related bloodstream infection 132 
6.5 Prevention and treatment of intestinal failure associated liver disease  133 
6.6 Non-transplant surgery and intestinal transplantation 134 
6.7 Transition from childhood to adulthood of chronic intestinal failure patients 135 
6.8 The economic and social burden of chronic intestinal failure  136 
7. Conclusions and future view for clinical and research networking 137 
Conflict of interest   138 
Acknowledgment  139 
References  140 
141 
5 
 
1. Introduction 142 
Intestinal failure (IF) is defined as “the reduction of gut function below the minimum 143 
necessary for the absorption of macronutrients and/or water and electrolytes, such that 144 
intravenous supplementation (IVS) is required to maintain health and/or growth”[1]. According to 145 
functional criteria it is classified as type I acute intestinal failure (AIF), type II prolonged AIF and 146 
type III chronic intestinal failure (CIF)[1]. It may be due to one or more of five major 147 
pathophysiological mechanisms that may originate from various gastrointestinal or systemic, 148 
congenital or acquired, benign or malignant diseases. A clinical classification of CIF has been 149 
devised on the basis of the IVS requirements[1] (BOX 1). The ESPEN Workshop on IF was held in 150 
Bologna, Italy, on 15-16 October 2017 focused on IF due to benign disease. 151 
 152 
2. Epidemiology 153 
The only available data on the type II-prolonged AIF were provided by a British study in 154 
2006, which estimated an annual incidence of 9 patients per million population[2]. Surgical 155 
complications (32%), Crohn's disease (21%), motility disorders (14%), intestinal ischaemia (13%) 156 
and malignancy (8%) were the main underlying causes[2]. 157 
The epidemiology of CIF is based on the data from home parenteral nutrition (HPN) which 158 
often include patients with either benign or malignant diseases. In Europe, the prevalence of HPN 159 
for CIF has been estimated to range from 5 to 80 per million population, with the incidence 160 
ranging from 7.7 to 15 IF/HPN patients/million inhabitants/year[1, 3-5]. Around 10% of patients 161 
were in the paediatric age group[1, 3-5].  162 
The 2015 data collection for the ESPEN “CIF Action Day” database, included 2919 adult 163 
patients with benign CIF from 65 HPN centers from 22 countries and gave an updated picture of 164 
the mechanisms and the underlying diseases of CIF[6]. Short bowel syndrome (SBS) was the most 165 
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frequent pathophysiological mechanism of CIF (64.3%): 36.8% had an end jejunostomy and the 166 
remaining had part (19.9%) or all of the colon (5.9%) in continuity. Intestinal dysmotility was 167 
present in 17.5% of cases, intestinal fistulae in 7.0%, mechanical obstruction in 4.4% and extensive 168 
mucosal disease in 6.8%. The most frequent underlying disease was Crohn's disease (22.4%), 169 
followed by mesenteric ischaemia (17.7%), surgical complications (15.8%), primary chronic 170 
intestinal pseudo-obstruction (9.7%) and radiation enteritis (7.3%). Furthermore, the data 171 
indicated that IVS reflects loss of intestinal function better than energy requirements and allowed 172 
formulation of the simplified revision of the formerly proposed 16-category clinical classification of 173 
CIF[6]. Strategies to have constantly updated data on incidence and prevalence of AIF and CIF are 174 
required to allow adequate allocation of resources from the healthcare systems. 175 
 176 
3. Identification of intestinal failure  177 
IF is the rarest type of organ failure. Although publications on “intestinal failure” appear in 178 
PubMed from 1980, IF is not yet included in the list of MeSH terms[7]. In 2013, CIF due to benign 179 
disease has been included in the ORPHANET list of rare disease (ORPHA:294422)[8]. In addition, 180 
CIF is not yet recognized in the International Classification of Disease (ICD) and is not supported 181 
uniformly by national health care services[9]. Strategies to identify IF are warranted to allow 182 
national healthcare systems to devise appropriate regulations and structures (i.e.: hospital units, 183 
multiprofessional teams) for the management of IF.  184 
 185 
4. Multidisciplinary management of intestinal failure 186 
The aims of management of patients with IF are to provide IVS, to reduce the severity of IF, 187 
to prevent and treat complications, including those related to the underlying disease, IF itself or its 188 
treatments, and to achieve good quality of life for patients[10].  189 
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Multi-disciplinary teams (MDT) are the key to successful management of IF. This was 190 
proposed by Nehme[11] in 1980, after finding that patients requiring IVS who were organised, 191 
supported and managed by a nutrition support team (NST) were less likely to develop catheter 192 
related bloodstream infection (CRBSI) at 24 months than those managed by a variety of physicians 193 
(1.3% versus 26.2%).  194 
The earliest establishment of HPN was as an extension of hospital care provided by the 195 
team that cared for the patient whilst in hospital. This was not universal, was frequently driven by 196 
a limited number of people and required thorough succession planning to ensure longevity[12].  197 
In the USA, intestinal care centres were established to provide intestinal rehabilitation, but 198 
these were mostly focused upon CIF for weaning off HPN, reducing complications and preparing 199 
patients for intestinal transplantation (ITx)[13].  200 
The concept of AIF, however, is a more recent one, which has brought with it the idea of a 201 
specialised intestinal failure unit (IFU) where specialist care is focused in one particular ward or 202 
area[2, 14]. The main aims of these IFUs are to provide consistency of expert care for safe IVS and 203 
catheter care to minimise rates of CRBSI, maintain accurate fluid balance, provide stoma and 204 
wound care, distal feeding (enteroclysis) and psychological care, all from highly trained and 205 
specialised nurses. A full range of specialists should be available at these IFUs, including constant 206 
‘expert’ medical and surgical care, dieticians, pharmacists, psychologists/psychiatrists and 207 
interventional radiologists, with admission of patients for purely IF-related issues. There is 208 
evidence that such specialised IFUs, providing a skilled MDT, reduce complication rates and 209 
mortality[2, 12]. 210 
 211 
5. Acute intestinal failure 212 
5.1 Assessment of type II prolonged-acute intestinal failure 213 
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The ESPEN classification of AIF is based primarily on duration and does not comprise any 214 
severity categorization. As organ dysfunction in critical illness is commonly graded according to 215 
severity, the Working Group on Abdominal Problems (WGAP) of the European Society of Intensive 216 
Care Medicine (ESICM), proposed four grades of Acute Gastrointestinal Injury (AGI), based on 217 
motility disorders leading to intolerance of enteral nutrition and progressing to gastrointestinal 218 
injury[15]. The ESPEN type I-AIF could be associated with AGI grade I due to impaired 219 
gastrointestinal motility, whereas the type II-prolonged AIF could be associated with AGI grades II 220 
to IV, due to impaired gastrointestinal motility progressing to gastrointestinal mucosal injury, with 221 
clear mucosal injury (e.g. bowel ischaemia and necrosis) seen in AGI Grade IV. Evaluation of 222 
gastrointestinal function in AIF is mainly based on bedside clinical assessment, which is largely 223 
subjective and not well reproducible, whereas searches for specific marker(s) allowing dynamic 224 
evaluation are continuing[16]. 225 
5.2 Intestinal ischemic injury as a cause of acute intestinal failure 226 
Aside from these classifications of AIF, the concept of acute intestinal ischemic injury (i3) 227 
has been proposed to standardize and organize a management pathway that can be extended to 228 
all AIF, whatever the mechanisms[17]. Acute i3, defined as an acute intestinal injury secondary to 229 
a vascular insufficiency, can be present in the type I and type II ESPEN functional classification of 230 
AIF, as well as in grades I to IV of AGI. The vascular insufficiency can be occlusive (arterial/venous 231 
from thrombosis, embolus, dissection, trauma, tumoral invasion) or non-occlusive (low cardiac 232 
output, decreased blood pressure, vasoconstriction, venous stasis). The intestinal injury occurs at 233 
different degrees of depth (superficial versus transmural), and at different stages of progression 234 
(early/late, reversible/non reversible, necrotic/non-necrotic). Early and superficial i3 can be 235 
reversible whereas late, necrotic and transmural i3 are irreversible[17-20]. The loss of the 236 
intestinal barrier function and translocation of luminal contents are the cornerstone of 237 
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deterioration and lead to a local, regional and then systemic inflammatory response syndrome 238 
(SIRS) and multiple organ dysfunction syndrome (MODS). 239 
A gut and lifesaving multimodal strategy has been proposed[18], including a wide range of 240 
specialists for the management of i3 (Box 2). Following the diagnosis of acute i3 a multimodal 241 
protocol should be implemented. If the patient is in the early stages of ischaemia then radiological 242 
revascularisation is generally recommended, with surgical revascularisation if necessary. In the 243 
late and irreversible phases, surgical revascularisation and intestinal resection are the mainstays of 244 
management. In a pilot study, patients managed using this multimodal management strategy had 245 
a 95% survival at 30 days, with mean lengths of intestinal resection of 30 cm and 207 cm, with or 246 
without revascularisation respectively[18]. Recently in the dedicated intestinal stroke center 247 
(SURVI) an overall survival of 86% and intestinal resection rates of 27 % have been reported[21].  248 
 249 
5.3 Nutrition therapy and fluid and electrolyte balance 250 
In the management of AIF, there exist different phases, directed to achievement of 251 
different goals (Figure 1). Throughout the course, both hypo- and hyper-volaemia should be 252 
avoided. In the initial unstable and acute phase of illness capillary leak is observed which leads to 253 
hypovolaemia and resultant tissue oedema. There are no clear surrogate markers to quantify the 254 
magnitude of the fluid shift, whereas prolonged hypovolaemia is known to aggravate capillary 255 
leak. Excessive fluid infusion and hypervolaemia result in bowel oedema, which is more 256 
pronounced in injured bowel. This hampers local transport of oxygen and nutrients and impairs 257 
anastomotic healing[22-24]. A number of mechanisms influence the occurrence of bowel oedema: 258 
capillary leak precipitated by inflammation; increased hydrostatic pressure from hypervolaemia; 259 
increased mesenteric venous pressure due to mechanical ventilation, increased intra-abdominal 260 
pressure or right heart failure; low oncotic pressure resulting from hypoalbuminaemia; impaired 261 
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intestinal lymph flow due to impaired bowel motility, increased intra-abdominal pressure and 262 
mechanical ventilation.  263 
Initial fluid administration aims to achieve haemodynamic, tissue perfusion and oxygen 264 
delivery goals. Severe hypovolaemia should be avoided as this leads to severe vasoconstriction 265 
and activation of the pro-inflammatory cascade. Once hypovolaemia has been corrected, 266 
vasodilation commonly occurs and should be treated with vasopressors rather than additional 267 
fluids. At the same time, treating severe hypovolaemia with vasopressors is harmful and achieved 268 
normal blood pressure does not indicate adequate tissue perfusion. Balanced crystalloids should 269 
be used in initial resuscitation. Synthetic colloids may expand the intravascular volume more 270 
effectively, but have been associated with renal dysfunction[25]. Replacement of fluids in a later 271 
stable phase can usually be guided by measured fluid losses and aim for normal distribution of 272 
body water, not only expansion of plasma volume. 273 
In terms of nutritional support, the preferred hierarchy generally ranges from oral intake to 274 
gastric then jejunal nutrition to parenteral nutrition. Oral intake is not adequate in most critically 275 
ill patients and may carry the risk of aspiration. In the acute phase, early nutrition aiming to meet 276 
the patient’s full caloric requirements is harmful, but the optimal amount of calories and protein 277 
necessary in this early stage is not well established. Parenteral nutrition should be considered if 278 
enteral nutrition is not established within one week. Feeding via the enteral route is preferable as 279 
it may prevent mucosal atrophy and help preserve the microbiome, but it is difficult to monitor 280 
malabsorption in this setting. A combined feeding strategy such as oral and enteral or enteral and 281 
parenteral nutrition is, however, known to increase the risk of overfeeding[26]. Contraindications 282 
to enteral feeding are summarized elsewhere[27]. In patients with high output fistulae or stoma 283 
and achievable distal access, a chyme reinfusion (enteroclysis) should be considered[28].  284 
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Electrolyte balance is also crucial in the management of AIF, particularly as low 285 
concentrations of potassium, magnesium and phosphate are associated with impaired bowel 286 
motility[29] and development of the refeeding syndrome[30]. In case of ileus, high-normal 287 
concentrations of these electrolytes could be beneficial, but evidence proving such benefit is 288 
lacking. Electrolyte concentrations should be monitored closely, particularly in the setting of 289 
insulin administration, which may shift potassium, magnesium and phosphate from the 290 
extracellular to the intracellular compartment, and lead to overt refeeding syndrome. Losses are 291 
frequently unpredictable in AIF, and an intimate understanding of the site of absorption of fluids, 292 
electrolytes and nutrients is the key enable anticipation of the impact of resection or bypassed 293 
areas of the gastrointestinal tract.  294 
5.4 Stoma and wound care 295 
High output stomas including enterocutaneous fistulae and complex ostomies as related to 296 
type II-prolonged AIF are associated with negative outcomes[31]. Protocols exist for the 297 
management of high output stomas, including detection and treatment of the underlying cause, 298 
reduction of fluid and electrolyte losses, optimisation with anti-secretory and anti-diarrhoeal 299 
medication and ongoing evaluation of efficacy or additional treatment if the high output 300 
continues[32-34].  301 
It is particularly important that patients who require monitoring are identified correctly, 302 
and that the fluid balance charts are completed accurately, including drain(s) and stoma outputs. 303 
Explaining to the patient the reasoning behind fluid restriction has also been shown to improve 304 
compliance. Careful observation is recommended, including a measure of size, appearance, 305 
function and separation between the stoma and skin surrounding the stoma. A range of 306 
appliances is available for expert management of complex stoma and fistulae to maintain skin 307 
integrity and minimise leakage.  308 
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Laparotomy wounds require an individualised treatment plan describing the surface of the 309 
wound, including: length, width, depth, eventual undermining or granulation and surrounding 310 
skin. Stomas and wounds must be separated, in order to secure proper healing and reduce 311 
infections. As for stomas, a variety of appliances for wound management exist. The stoma and 312 
wound care nurse specialist must stock a variety of the necessary products and be familiar with 313 
their use. Topical negative pressure (TNP) may be used for large wounds or when undermining is 314 
more than 5 cm. It may also be used, when drainage of the wound is desired, and where the 315 
wound healing is not progressing. TNP is contraindicated in wounds with necrotic tissue, and in 316 
those with visible blood vessels[35].  317 
Fluid restriction carries a risk of oral cavity problems such as mouth sores, xerostomia, 318 
thick saliva and fungal infection. Evidence-based oral care, in the form of chlorhexidine 319 
mouthwash, glycerol products, crushed ice, and lip care, may reduce the risk of aspiration 320 
pneumonia[36].  321 
 322 
5.5 Prevention and management of sepsis 323 
Sepsis is the leading cause of death in AIF. Sepsis may originate from the abdominal cavity, 324 
be caused by bacterial translocation (e.g. in case of severe bowel distension, subacute bowel 325 
ischemia without perforation, etc.), a CRBSI or extraabdominal causes (such as pneumonia or 326 
urinary tract infection). Sepsis can present with a wide spectrum of symptoms/signs including 327 
impairment of gastrointestinal or hepatic function, fluid retention and oedema, fever, increased 328 
metabolic demand and impaired fuel utilisation, insulin resistance and failure to thrive[2]. 329 
Abnormal laboratory parameters include elevated C-reactive protein and leucocyte counts, 330 
hypoalbuminemia, hyponatraemia and abnormalities in liver function tests. However, clinical signs 331 
may be absent in up to 50% of patients, particularly in the severely malnourished[37]. Diagnostic 332 
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modalities include CT scanning which has an accuracy exceeding 95% and may provide a 333 
therapeutic as well as diagnostic opportunity, ultrasound, MRI, radionucleotide studies and 334 
fluoroscopy. These imaging modalities should be supported by cultures from peripheral veins and 335 
any indwelling lines, urine and wound swabs, chest imaging, and a thorough search should be 336 
made to identify a source of sepsis[2, 14]. In the setting of a proven intra-abdominal collection, a 337 
minimally invasive approach is recommended in an expedient manner, in the form of either CT or 338 
ultrasound-guided drainage, via percutaneous or alternative routes (e.g. trans-gastric, trans-339 
gluteal, trans-rectal or trans-vaginal. This should be supplemented by antibiotic therapy which 340 
should be guided by microbiological review of cultures. Should a minimally invasive route not be 341 
an option, surgical drainage is indicated.  342 
Control of sepsis is the primary objective in the management of AIF and some centers use 343 
acronyms such as SOWATS (sepsis control, optimisation of nutritional status, wound care, 344 
anatomy of the bowel and the fistula, timing of surgery, surgical planning)[37] and SNAP (Sepsis-345 
Nutrition-Anatomy-Plan)[14] which help navigate treatment pathways. 346 
 347 
6. Chronic intestinal failure 348 
6.1 Short bowel syndrome: spontaneous and induced intestinal adaptation after resection 349 
Short bowel syndrome is the most frequent pathophysiological mechanism of CIF in 350 
adults[6]. A functional small bowel <200 cm affords an accepted anatomical definition of short 351 
bowel in adults, but some authors prefer to limit the term to patients with <150 cm[1]. The 352 
incidence of SBS is about 2 per million per year and the prevalence about 20 per million[38], 353 
however, the exact epidemiology is not known. 354 
SBS is categorized into three types: a) end-jejunostomy (SBS-J); b) jejunocolic anastomosis, 355 
where the remnant jejunum is in continuity with part of the colon, most frequently left colon (SBS-356 
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JC); c) jejuno-ileal anastomosis with ileo-caecal valve and the intact colon in continuity (SBS-357 
JIC)[38,39].  358 
Pathophysiologically, SBS can be classified into two subgroups, those with intact colon or 359 
part of it in continuity and those without colon in continuity[38-40]. These subgroups differ in 360 
three key characteristics: intestinal water and sodium absorption, gastrointestinal hormone 361 
secretion and energy absorption from short chain fatty acid (SCFA) produced by the colon 362 
microbiota.  363 
Gastrointestinal secretion is about 9 liters/day, with water and electrolyte absorption 364 
occurring predominantly in the distal small bowel and colon. Furthermore, in the jejunum, the 365 
intracellular tight junctions are relatively weak, and sodium absorption is coupled with the 366 
absorption of glucose (solvent drag) and occurs only against a concentration gradient. These 367 
mechanisms ensure rapid iso-osmolarity of the jejunal contents: hypertonic fluids cause the 368 
passage of water and hypotonic-low sodium fluids determine the secretion of sodium and water 369 
into the lumen. SBS-J patients often lose more fluid and sodium than ingested (net secretors), 370 
whereas in SBS-J and SBS-JIC there is usually sufficient distal bowel to permit fluid and electrolyte 371 
balance (net absorbers). The absorption of sodium and water in the colon are normally around 372 
200 mmol and 2 L/day in healthy adults and can increase up to 800 mmol and 6 L/day in SBS when 373 
the colon is in continuity[38-40]. 374 
Many gastrointestinal hormones and neuromodulators, which play a key role in the control 375 
of gastrointestinal secretions, motility and intestinal growth, are produced by the endocrine L-cells 376 
of the small intestinal and colonic mucosa. Peptide YY (PYY), glucagon-like peptide-1 (GLP-1) and 377 
GLP-2 are secreted in the distal ileum and the proximal colon after a meal, regulate motility by 378 
slowing gastric empting and small bowel transit (ileal brake) and exert a trophic effect on the 379 
mucosa by enhancing intestinal villus/crypt cell growth. The secretion of these hormones is 380 
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enhanced in SBS-JC and SBS-JIC and is reduced/absent in SBS-J. This translates to less or absent 381 
structural and functional adaptation after resection, and in accelerated gastric empting, especially 382 
for liquids in SBS-J[38, 41, 42]. The colon can contribute to the absorption of energy, as SCFAs, 383 
following the fermentation of non-absorbed carbohydrates by luminal bacteria. This mechanism 384 
can yield up to 1000 kcal/day (4 MJ) in patients with SBS and colon in continuity[43]. 385 
Spontaneous physiological intestinal adaptation after massive small bowel resection occurs 386 
during the following two to three years, and improves intestinal absorption through intestinal 387 
mucosa hyperplasia, slowing of gastrointestinal transit, modified gastrointestinal hormonal 388 
secretion (GLP-1, GLP-2 and PYY)[38, 41, 43], development of hyperphagia[44] primarily 389 
stimulated by an increased secretion of the orexinogenic gut hormone, ghrelin[45], and alteration 390 
of the gut microbiota with a higher prevalence of Lactobacillus and a fewer anaerobes (Clostridium 391 
leptum and Bacteroides spp.)[46] and an accumulation of faecal d/l-lactate in some patients[47]. 392 
These changes are stimulated by intraluminal nutrients and pancreatico-biliary secretions and are 393 
highly variable and unique to each patient.  394 
The ESPEN guidelines additionally describe induced intestinal adaptation based on dietary 395 
counseling, oral rehydration solution and drugs to slow gastrointestinal transit and decrease 396 
intestinal secretion, as well as antibiotics to treat intestinal bacterial overgrowth, when this 397 
occurs[12]. Patients are advised a hypercaloric diet, divided into 5-6 meals. Simple sugars should 398 
always be limited, lipids limited when colon is in continuity, and fibre limited when there is an end 399 
jejunostomy. Hypo-osmolar low-sodium fluids should be avoided because they increase intestinal 400 
losses. The consumption of 500-1000 ml/day of oral rehydration solution according to the World 401 
Health Organization formula may favour intestinal absorption of water and electrolytes. Proton 402 
pump inhibitors at full dosage can reduce intestinal fluid losses by decreasing gastric secretion. 403 
Loperamide and codeine phosphate  slow intestinal transit safely. Octreotide decreases 404 
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gastrointestinal secretion and slows gastrointestinal motility, and can be useful in individual 405 
patients for a short time. This “conventional” therapy for SBS is, however, supported by very few 406 
studies[12].   407 
The probability of weaning a patient from HPN with the combination of spontaneous 408 
intestinal adaptation, dietary counselling and conventional therapy depends on the length, 409 
integrity and anatomy of the residual bowel in continuity. The minimum small bowel length for 410 
independence from PN has been reported to be 35 cm in SBS-JIC, 60 cm in SBS-JC and 115 cm in 411 
SBS-J[48], provided that the remnant bowel is healthy, but CIF and HPN dependence may occur 412 
when longer remnants (e.g. >200 cm) are diseased and sometimes without overt pathology, a 413 
condition termed functional SBS[1, 12]. 414 
 415 
6.2 Short bowel syndrome: enhanced post-resection intestinal adaptation 416 
In the last two decades, gastrointestinal hormonal factors have been investigated and used 417 
for intestinal rehabilitation of patients with SBS, with the aim of maximizing absorption in the 418 
remnant bowel, decreasing intestinal losses, and reducing the need for intravenous 419 
supplements[49]. At present, the only one approved by the FDA and EMA for clinical use is the 420 
GLP-2 analogue, teduglutide[50]. Randomized clinical trials have demonstrated its efficacy in 421 
reducing intravenous supplements in around two-thirds of patients treated so far, a small number 422 
having been able to be weaned off HPN[51, 52]. However, long-term benefits and risks still need 423 
to be elucidated and, therefore, regular and expert follow-up is strongly advisable. Furthermore, 424 
this treatment is costly, and the cost-efficacy as well as the risk-benefit ratio need to be evaluated. 425 
A few open-label studies investigated the usefulness of GLP-1 analogues, liraglutide[53, 54] 426 
and exenatide[55]. Encouraging results have been observed, but have to be validated by 427 
controlled trials. 428 
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 429 
6.3 Outcome on home parenteral nutrition 430 
Patients on HPN for CIF may develop central venous catheter (CVC) or metabolic 431 
complications due to factors related to HPN and/or the underlying disease, that may eventually 432 
cause death[12, 56]. Patients also suffer commonly from psychological problems and an impaired 433 
quality of life as a result of their underlying disease and the burden of HPN[56]. A review of 11 434 
published series demonstrated that 53% of patients with benign CIF requiring HPN died as a result 435 
of their underlying disease with only 14% dying because of HPN-related complications; of the 436 
latter, 8% occurred as a result of catheter-related bloodstream infection (CRBSI), 4% from intestinal 437 
failure associated liver disease (IFALD) and 2% from CVC-related venous thrombosis[57]. 438 
 439 
6.4 Prevention and treatment of catheter-related bloodstream infection 440 
Older[58, 59], as well as recent[12], international guidelines advise that the diagnosis of 441 
CRBSI should be based upon quantitative and qualitative assessment of CVC and peripheral blood 442 
cultures. Quantitative blood cultures – counting colony forming units - are the most accurate test 443 
for the definitive diagnosis of CRBSI[59]. However, not all IFUs follow such guidance. Indeed, a 444 
recent study noted that basing the diagnosis of CRBSI on clinical assessment only, rather than 445 
following ESPEN guidance, may lead to over diagnosis of CRBSIs by 46%, which can, in turn, lead to 446 
inappropriate antibiotics and increased risk related to repeated CVC re-insertion[58]. Further work 447 
is required to address the barriers to units adopting standardised, internationally agreed, 448 
protocols to define CRBSIs in patients needing HPN, not least because of the importance placed on 449 
CRBSI rate as a quality assurance measure[60]. Furthermore, the role of new diagnostic 450 
approaches, such as real-time polymerase chain reaction, aimed at improving diagnostic sensitivity 451 
and reducing time to diagnosis, requires further evaluation[14]. 452 
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Once infected, CVC salvage is paramount to preserving long term venous access[12]. Two 453 
recent and large retrospective series from England[61] and the USA[62] demonstrated that 454 
successful salvage can be achieved following CRBSI in patients with CIF using standardised 455 
protocols involving systemic and local antibiotic therapy. Apparent differences between these 456 
studies highlighted that there remain a number of debated issues relating to CVC salvage, 457 
including a consensus on salvaging specific microbial isolates, the duration of salvage therapy and 458 
the definition of successful salvage. CRBSI rates vary greatly between institutions both nationally 459 
and internationally, with reported occurrences between from 0.14 to 1.09 episodes per catheter 460 
year[12]. Although ESPEN guidelines are clear on standard approaches to prevention of CRBSI – 461 
including education of staff, implementation of handwashing policies, hub disinfection, use of 462 
tunneled single lumen catheters – it is clear that there is limited evidence for novel approaches 463 
such as antimicrobial lock therapy[12]. There is good evidence that ethanol locks should not be 464 
recommended due to the risk of catheter occlusion and damage[12], while a recent multicenter 465 
randomised study showed the efficacy of taurolidine lock to reduce the risk of CRBSI significantly 466 
in new implanted CVC[63].  467 
 468 
6.5 Prevention and treatment of intestinal failure associated liver disease 469 
Liver injury in CIF can occur as a result of nutrient and non-nutrient factors. The former 470 
may include calorie overfeeding and/or nutrient deficiencies, including choline, taurine and 471 
carnitine. Non-nutrient factors include recurrent episodes of sepsis, bacterial overgrowth, SBS, 472 
hepatotoxic medications and underlying parenchymal liver disease[12, 56]. Retrospective series 473 
reveal a significant variation in the reported incidence of advanced liver disease from 0-85%[64-474 
67]. Although such variation may have related to the amount of soybean-based lipid administered 475 
routinely in clinical practice in the past, it is apparent that a standardised definition of IFALD is 476 
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required to allow comparison between individual centres and series. To-date, most studies on 477 
IFALD relied on biochemical abnormalities rather than histological information; for example, 478 
chronic cholestasis has been defined as the persistent elevation greater than 1.5 times the upper 479 
limit of the normal range for more than 6 months of two of the biochemical parameters: alkaline 480 
phosphatase, gamma-glutamyl transferase and conjugated bilirubin[64-66]. However, since liver 481 
function tests may not correlate with the severity of underlying liver disease, a consensus 482 
approach to the diagnosis and categorisation of IFALD is required that synthesises clinical, 483 
biochemical, radiological and histological parameters. Indeed, since deterioration of liver disease 484 
may not be reflected by changes in standard biochemical parameters, serial liver biopsy is still the 485 
gold standard for assessing IFALD[68]; this is, of course, of paramount importance in patients 486 
considered for isolated small bowel vs. multivisceral transplantation[12]. The role of alternative, 487 
non-invasive approaches to liver biopsy, including transient elastography, MR spectroscopy and 488 
quantitative ultrasound has been considered[12]. A multicentre study demonstrated that transient 489 
elastography values correlated with the serum bilirubin concentration, the severity of histologic 490 
cholestasis, the AST to platelet ratio and the FIB-4 score, but not to the histologic fibrosis 491 
stage[69]. Further work is required to evaluate the role of these imaging techniques, in tandem 492 
with further assessment of the efficacy of specific serological markers of hepatic fibrosis. 493 
Long-established approaches to prevent and/or treat IFALD are agreed: including cycling 494 
PN, maintaining oral or enteral intake and preserving small bowel length (wherever possible), 495 
avoiding PN overfeeding, limiting the dose of soybean-based lipid to less than 1 g/kg/day and 496 
minimising recurrent episodes of sepsis[12]. ESPEN guidelines recommend that the lipid profile of 497 
the PN admixture is modified to decrease the omega-6/omega-3 polyunsaturated fatty acid ratio; 498 
however, the evidence base for this recommendation is limited[12]. A 4-week randomised 499 
controlled, double-blind, multicentre study in 73 patients with CIF[70] demonstrated that 500 
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soybean/MCT/olive oil/fish oil emulsion was associated with lower concentrations of bilirubin and 501 
transaminases within the normal reference range compared to soybean-based lipid alone[71]. 502 
However, more data are required to evaluate the long-term efficacy, tolerance and safety of these 503 
and other novel combination lipids. Current evidence does not support the use of choline, taurine 504 
or carnitine to treat IFALD in adults, while limited data are available on the usefulness of 505 
ursodeoxycholic acid and of oral antibiotics to treat bacterial translocation[12]. A recent ESPEN 506 
position paper has focused on the definition and management of IFALD in adults with CIF.  507 
 508 
6.6 Non-transplant surgery and intestinal transplantation 509 
Alternative surgical treatments for CIF are ITx and autologous gastrointestinal 510 
reconstructive surgery (AGIRS)[72, 73]. The AGIRS may aim to improve intestinal motility in case of 511 
a dilated bowel, to slow intestinal transit in the absence of bowel dilatation or to increase mucosal 512 
surface area. When AGIRS is indicated, the first option should be restoration of small bowel 513 
continuity in case of unused intestinal segments[12]. The most widely accepted timing for 514 
restoration of bowel continuity is at 3-6 months after the acute event, even though period as short 515 
as 7-10 days could be considered in the “non-hostile” abdomen[12, 73]. The AGIR procedures for 516 
SBS are categorized as tapering enteroplasty or plication, reversed intestinal segments (adult 517 
patients), colonic interposition (rarely performed nowadays), intussusception valve (in paediatric 518 
population to induce bowel dilation) and the lengthening procedures, which are the most 519 
frequently performed in patients with SBS[72, 73].  520 
Lengthening procedures are of choice in case of a rapid intestinal transit and bowel dilation 521 
(up to 5 cm). In the absence of bowel dilation, reversed segment[74, 75], colonic interposition[76] 522 
or neovalve procedures are used[77], the last one to obtain sequential dilatation and then use the 523 
lengthening procedures. There are 4 types of lengthening procedures: longitudinal intestinal 524 
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lengthening (LILT) or Bianchi’s procedure[78], serial transverse enteroplasty (STEP), first described 525 
in 2003[79], the Kimura’s technique (no more used today)[80] and the spiral intestinal lengthening 526 
and tailoring (SILT) procedure, firstly described in 2011[81].  527 
Most of the published data are on pediatric patient cohorts. The LILT procedure is a very 528 
complex type of surgery, where the dilated bowel is divided longitudinally. Each half longitudinal 529 
portion is tubularised and the two new segments are anastomosed end-to-end[78]. In the STEP 530 
surgery, serial transverse surgical stapler is applied on the dilated bowel and the new elongated 531 
intestinal channel has a zig-zag appearance[79]. In the SILT procedure, the bowel is incised along 532 
spiral lines and stretched to a uniformly longer tube of narrower diameter and the bowel is 533 
sutured along the incision line[81]. While no data comparing SILT with the other lengthening 534 
procedures are available, LILT and STEP have been compared, with a greater worldwide 535 
experience for STEP[72]. Surgical complexity is higher with LILT, that requires significantly more 536 
mesenteric handling. The LILT procedure cannot be performed in the duodenum and needs a 537 
residual bowel length of at least 20-40 cm. The STEP procedure can be performed with any length 538 
of bowel and even in the duodenum and is therefore of choice for ultra-short SB (<20 cm). The 539 
STEP can be repeated in the same patient and can also be performed in those who have already 540 
undergone LILT (which cannot be repeated). Furthermore, STEP has been demonstrated to be 541 
successful in the treatment of intestinal bacterial overgrowth and the associated D-lactic acidosis. 542 
Complications such as intestinal bleeding, obstruction and leakage have been described with both 543 
the procedures, whereas intestinal necrosis, perforation, fistula and abscess have been reported 544 
only after LILT. The results indicate a trend toward a higher percentage of intestinal lengthening 545 
with STEP (up to 69%) than with LILT (up to 55%), lower need of ITx after STEP (5-6% compared 546 
with 10-26% after LILT), whereas the two procedures showed similar percentages of PN 547 
independence (55-60%) and of survival (up to 90%)[73].  548 
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 Intestinal rehabilitation programmes based on medical treatment and AGIRS can improve 549 
intestinal function and allow weaning off HPN. Patients with irreversible CIF are destined to life-550 
long HPN or ITx. On the basis of data on safety and efficacy, HPN is considered the primary 551 
treatment for CIF, whereas ITx is reserved for those patients at risk of death because of life-552 
threatening complications related to HPN or the underlying gastrointestinal disease[12]. Published 553 
cohorts showed mean 5 and 10-year survival rates on HPN of 70% and 55% in adults, and 89% and 554 
81% in children[57]. HPN complications were the cause of 14% of deaths in adults and of up to 555 
70% of deaths in babies <1 year[57]. The 2013 International Transplant Registry report showed a 556 
5-year patient survival rate of 40-60% in adults and 50-70% in children, depending on the type of 557 
transplant with the best results after isolated small bowel ITx. Almost all the deaths after ITx were 558 
related to the treatment[82]. 559 
The indications for ITx were firstly developed by expert consensus in 2001 and could be 560 
categorized as HPN failure (liver failure due to IFALD; CRBSI, CVC-related vein thrombosis and 561 
chronic dehydration), high risk of death due to the underlying disease (invasive intra-abdominal 562 
desmoids, congenital mucosal disease, ultra SBS) or very poor quality of life (intestinal failure with 563 
high morbidity or low acceptance of parenteral nutrition)[39, 83]. Those indications were 564 
challenged by a 5-year prospective survey carried out by the HAN&CIF group ESPEN. The results 565 
allowed to define that only intra-abdominal desmoids and IFALD-liver failure were associated with 566 
an increased risk of death on HPN[84-86]. Therefore, the ESPEN guidelines recommend that those 567 
conditions should be considered indications for straight referral for a life-saving ITx. The early 568 
referral of patients with CIF to intestinal rehabilitation centers with expertise in both medical and 569 
surgical treatment for CIF is recommended to maximize the opportunity of weaning off HPN, to 570 
prevent HPN failure, and to ensure timely assessment of candidacy for ITx[12]. Indeed, the 571 
number of transplants performed per year had steadily increased until 2009, after which it 572 
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declined steadily, due to improvement in HPN management and to advances in intestinal 573 
rehabilitation[82, 87, 88].  574 
 575 
6.7 Transition from childhood to adulthood of CIF patients 576 
Transition describes the process by which medical care for adolescents with chronic 577 
disorders is handed over from the pediatric to the adult team. Patients deals this process with a 578 
mix of emotional feelings that range from anxiety generated by leaving the familiar environment 579 
of the pediatric centers to the enthusiastic dreams for a successful or at least as normal as 580 
possible life. Furthermore, the process from childhood to adulthood involves a lot of physiological, 581 
psychological, cognitive, social and economic changes.  582 
The transition from pediatric to adult CIF/HPN centers represents one of the major clinical 583 
challenge of the current era of CIF. The major issues for patients could be taking on the 584 
responsibility of administering the PN as well as other medications by themselves and of attending 585 
medical appointments and moving from personalized care in a family centred paediatric unit to a 586 
large, possibly more impersonal, centre. The paediatric and the adult centres are required to 587 
collaborate in order to clarify any confusion around care routines and psychological problems and 588 
to educate the young persons about their illness, helping the patient to understand the condition 589 
and its management and to realise the serious implications of non-compliance with medical 590 
advice. This seems to be a key issue because patient underestimating or psychologically denying 591 
the severity of the illness may favor the occurrence of major HPN/underlying disease 592 
complications, representing a major risk factor for death during the transition period.  593 
No guidelines have yet been provided about this process. The British Association of 594 
Parenteral and Enteral Nutrition (BAPEN) and the British Society of Paediatric Gastroenterology 595 
and Nutrition (BSPGHAN) investigated this issue sending a dedicated questionnaire to their 596 
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members[89]. The main findings are summarized in BOX 3. It was concluded that transition 597 
pathway and service standards for adolescents on home PN should be developed, consideration 598 
should be given to checklists for practical aspects (e.g. pumps), key worker and psychology input 599 
to enhance emotional resilience of the young people and careers. 600 
 601 
6.8 The economic and social burden 602 
CIF may result in a lifelong dependence upon HPN, which carries a high complication rate 603 
and may impact upon overall patient survival. The provision of HPN is directly related to the 604 
national economic status and is particularly controversial in the setting of end-stage malignancy 605 
where the HPN-complication rate is higher.  606 
The ESPEN guidelines for CIF[12] recommend that a HPN programme includes the 607 
“provision of evidence-based therapy, prevention of HPN-related complications… and ensure 608 
quality of life is maximised”. A recently published international retrospective study[90] of 472 609 
patients with severe chronic and benign IF who commenced HPN in 2000 demonstrated a survival 610 
probability of 88%, 74% and 64% at 1, 3, and 5 years, with survival inversely associated with 611 
increasing age, the presence of Crohn’s disease or chronic idiopathic pseudo-obstruction. At 5-612 
year follow up, 39% were alive on HPN with a mean age of 55 years, 36% had been weaned from 613 
HPN with a mean age of 52 years, 22% had died on HPN with a mean age of 60 years, 2% were 614 
alive following intestinal transplant with a mean age of 42 years and 1% had died following 615 
intestinal transplant with a mean age of 36 years. The probability of HPN dependency at 5 years is 616 
variable depending on the cause of the original HPN requirement, with a significantly increased 617 
risk of remaining on HPN at 5 years in those with SBS versus a much lower risk in those with an 618 
intestinal fistula. When 1,2, and 5-year survival in patients with CIF is compared between 619 
literature from 1999[33] and 2017[90], very little change has been observed (87 vs. 88%, 77 vs. 620 
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80%, and 62 vs. 64%). The underlying disease process remains responsible for 65% of deaths 621 
within this cohort.  622 
In the United Kingdom the cost of HPN is estimated at £30,000-40,000 per year if the 623 
patient is self-caring, and £55,000-65,000 if they require nursing support, whereas ITx is estimated 624 
to cost £80,000 in the first year then £5,000 per year after, thus making this intervention cost-625 
effective after two years[91]. The story is similar in the Netherlands where HPN is estimated at 626 
€63,000 per year and ITx at €73,000 per year[92], thus the economic burden of IF is huge. 627 
Infectious complications related to HPN also carry a significant economic burden, with CRBSI 628 
accounting for 0.4-3 incidences per 1,000 catheter days and 70% of HPN-related hospital 629 
admissions. Each CRBSI is estimated to cost around €6,480 per admission[93].  630 
The social implications of IF are wide ranging, including disruption from pre-IF social and 631 
work life, uncertainty arising from HPN-related problems which frequently occur on an emergency 632 
basis and a changed perspective upon life. Depression is estimated at a rate of 65% in this 633 
population, and severe fatigue at 63%[94]. A study of 110 Dutch adult HPN patients found that 634 
76% had one or more episodes of CRBSI during their treatment[95], and this was strongly 635 
associated with psychosocial complaints and decreased quality of life[96]. This emphasised the 636 
lack of focus on the early recognition and treatment of psychosocial factors in patients on HPN.  637 
 638 
7. Conclusions and future view for clinical and research networking 639 
Both AIF and CIF are relatively rare conditions and most of the published work presents 640 
evidence from small, single-centre studies. Much remains to be investigated to improve the 641 
diagnosis and management of IF and future studies should rely on multidisciplinary, multicentre 642 
and multinational collaborations that gather data from large cohorts of patients. Some of the 643 
areas of future research are listed in Box 4. Emphasis should also be placed on partnership with 644 
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patients, carers and government agencies in order to improve the quality of research that focuses 645 
on patient-centred outcomes that will help to improve both outcomes and quality of life in 646 
patients with this devastating condition.  647 
648 
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Box 1 Definition and classification of intestinal failure[1, 6] 649 
Definition 650 
 Intestinal failure: the reduction of gut function below the minimum necessary for the absorption of 651 
macronutrients and/or water and electrolytes, such that intravenous supplementation (IVS) is required to 652 
maintain health and/or growth.  653 
 Intestinal insufficiency or deficiency: the reduction of gut absorptive function that doesn't require 654 
intravenous supplementation to maintain health and/or growth, can be considered as “intestinal 655 
insufficiency”  656 
 657 
Functional classification of intestinal failure 658 
Based on onset, metabolic and expected outcome criteria: 659 
▪ Type I - acute, short-term and usually self-limiting condition; this is a common feature, occurring in the 660 
perioperative setting after abdominal surgery and/or in association with critical illnesses; it recedes when 661 
those illnesses subside; IVS is required over a period of days or a few weeks 662 
▪ Type II - prolonged acute condition, often in metabolically unstable patients, requiring complex multi-663 
disciplinary care and IVS over periods of weeks or months.  664 
▪ Type III - chronic condition, in metabolically stable patients, requiring IVS over months or years; it 665 
represents the chronic intestinal failure (CIF), that may be reversible or irreversible. 666 
 667 
Pathophysiological classification 668 
Five major pathophysiological conditions, which may originate from various diseases: 669 
▪ short bowel 670 
▪ intestinal fistula 671 
▪ intestinal dysmotility 672 
▪ mechanical obstruction 673 
▪ extensive small bowel mucosal disease 674 
 675 
Clinical classification of chronic intestinal failure 676 
On the basis of the requirements for energy and the volume of the IVS, CIF was firstly categorized into 16 677 
subtypes. An international multicenter survey carried out by the CIF Action Day database allowed to 678 
simplify it in 8 categories[6]: 679 
 Volume of the IVS (mL/day)* 
Type of the IVS ≤ 1000 
1 
1001 - 2000 
2 
2001 - 3000 
3 
> 3000 
4 
Fluids and electrolytes (FE) FE 1 FE 2 FE 3 FE 4 
Parenteral nutrition (PN)  PN 1 PN 2 PN 3 PN 4 
 680 
* calculated as daily mean of the total volume infused per week = volume per day of infusion x number of 681 
infusions per week / 7 682 
FE = Fluids and Electrolytes alone 683 
PN = Parenteral Nutrition Admixture containing also macronutrients 684 
 685 
686 
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Box 2: Multimodal management strategy for acute mesenteric ischemia[18] 687 
 Assessment of Intestinal vascular perfusion which consists in a CT scan angiography at the 3 phases 688 
(non injected, arterial and portal phase) and the evaluation and control of cardiac and hemodynamic 689 
conditions. 690 
 Assessment of intestinal injury, by a combination of clinico-bio-scanographic features. In acute i3 the 691 
onset of organ failure and/or elevated blood lactates is highly predictive of intestinal transmural 692 
ischemic necrosis[6]. Non-specific clinical and biological manifestations can attest of intestinal injury: 693 
oral intolerance and motility disorders, blood losses, abdominal pain, diarrhea, persistent inflammatory 694 
syndrome, SIRS, altered liver function tests, anaemia, protein losing enteropathy, inflammation, 695 
hypoalbuminaemia. At CT-scan angiography intestinal injury features are mainly dilation, increase or 696 
decrease of mucosal enhancement, thickening/thinning, faeces signs, fat stranding mesentery, fluid 697 
collections. 698 
 Assessment of length of remnant small bowel, length, site, number of excluded segments, length and 699 
integrity of colon/rectum, stoma, drainages, presence/absence of the gallbladder. All these features 700 
should be indicated by the surgeon.  701 
 Assessment, identification and treatment of underlying and associated comorbidities at the origin of 702 
AIF. In case of acute i3 it can correspond to ischaemic and/or embolic and/or rhythmic and/or valvular 703 
cardiopathy. Predisposing thrombophilia should be explored.  704 
 Search for sepsis or fungal/bacterial colonisation or luminal bacterial overload especially in case of 705 
persistent inflammatory syndrome, high stoma output, oral intolerance, altered cognitive functions, 706 
persistent malnutrition. Physicians should detect and treat infection by repeated sampling of 707 
collections, abscesses, urine, lung (if symptoms), blood stream, scars and wall, catheters, swabs.  708 
 Optimisation and equilibration of the following parameters: 1) urine and stoma output with 709 
water/electrolytes balance, 2) nutrition (parenteral nutrition, enteral nutrition, distal enteral nutrition) 710 
and daily work-up of energy output/expenditure/input, 3) digestive functions with oral intake, 711 
treatment of motility disorders, protein losing enteropathy, 4) diabetes, 5) blood pressure and 712 
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anticoagulant therapy, 6) control of beverages, 7) wound care, 8) accesses (catheter, stoma), 9) 713 
psychology, nursing and social cares 714 
 Consideration at each stage of AIF of the question of the need for surgery: second look, emergency 715 
surgery, vascular rehabilitation, digestive rehabilitation. The criteria for surgery should always be 716 
discussed and planned a priori.  717 
 Evaluation and determination of the timing for each step of the strategy: closure of stoma, 718 
rehabilitation after nutritional recovery, cholecystectomy, surgical technics that promote intestinal 719 
adaptation (STEPS, segmental reversal of the small bowel), wound cares, home return and home 720 
parenteral nutrition.   721 
 Anticipation and prevention of complications of AIF: recurrence or complication of underlying disease, 722 
refeeding syndrome, hypernutrition, liver disease, respiratory complications, lines infections, stroke, 723 
anticoagulants.  724 
 725 
726 
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Box 3. Results of the BAPEN/BSPGHAN survey on transition of care from paediatric age group to 727 
adulthood[89] 728 
 729 
1) Transition can take as long as two years and is greatly facilitated by the appointment of an 730 
identified key worker for the young person. 731 
2) Psychological issues need to be addressed prior to transition. 732 
3) Written information can ensure clarity about all aspects of care.  733 
4)  Communication between the paediatric and adult centre is facilitated with at least one patient 734 
consultation where a professional from each centre is present.  735 
5) Aim to keep the same infusion pump after transition.  736 
 737 
738 
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Box 4. Areas for future investigation 739 
Identification, epidemiology and management of intestinal failure 740 
 Strategies to make AIF and CIF recognized at institutional, clinical and research levels 741 
 Studies to update incidence and prevalence of AIF type I and type II and CIF 742 
 Studies to demonstrate the positive cost-benefit ratio of the MDT in AIF and CIF management. 743 
 Strategies to increase the awareness of medical professionals on AIF type II and CIF 744 
 Acknowledgement of the role of nursing experts in IF with HOS and CO 745 
 Strategies to minimise the socioeconomic burden of CIF and HPN and to improve the patients’ 746 
quality of life 747 
 Strategies to homogenize HPN management (i.e., such as dialysis for chronic renal failure) in order 748 
to allow patient to receive the same high level of care, independently of the HPN center  749 
 Structured protocols for a successful transition from childhood to adulthood of patients with CIF 750 
 751 
Acute intestinal failure 752 
 Risk factors and outcome of AIF type I and II 753 
 Recognition, diagnosis and management of acute intestinal ischaemic injury (i3) 754 
 Biomarkers of acute intestinal ischaemic injury (i3), intestinal viability, mucosal perfusion and 755 
mucosal barrier integrity 756 
 Impact of type 1-2 IF on the onset and course of type 3 757 
 Markers of nutritional status and of hydration status in ICU patients 758 
 Medications to foster intestinal adaptation 759 
 Early prokinetics and laxatives in patients at risk for AIF type II 760 
 Early postpyloric EN vs. early PN in AIF type I patients with gastroparesis 761 
 Trophic EN vs PN in patients with AIF type I and at risk of AIF type II 762 
 Early liberal vs. conservative fluid strategy in abdominal surgical patients at risk for AIF type II 763 
 Electrolyte balance and GI motility in AIF type I and II 764 
 Early mobilization in AIF type II 765 
 Strategies to avoid post-operative fistula formation or encourage healing 766 
 Surgical and radiological techniques (including plugs and implants) to promote fistula closure 767 
 Impact of chyme reinfusion in ECF;  768 
 PPIs and fistula output 769 
 Role of bile salt signaling on the onset of liver test abnormalities in AIF type I and II 770 
 771 
Chronic intestinal failure 772 
 Short bowel syndrome 773 
 Safety and efficacy of intestinal growth factors in the very long term 774 
 Criteria to predict efficacy or failure of treatment with intestinal growth factors 775 
 Development of new intestinal growth factors 776 
 Safety and efficacy of high doses and prolonged use of opioids 777 
 Safety and efficacy of high doses and prolonged use of PPIs 778 
 Alternatives to WHO oral rehydration solution mixtures and the polysaccharide mixes which 779 
might be predicted to be better tolerated and more effective  780 
 Role of microbiota in post-surgical adaptation and metabolic complications 781 
 Intestinal stem cells transplantation to treat patients with intestinal failure 782 
 Parenteral nutrition admixture: 783 
o Lipids, role of emulsions containing fish oils 784 
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o Sugars, alternative to glucose 785 
o Amino acid profiles, better parallels with physiological and pathophysiological needs 786 
 Safety and efficacy of new oral anticoagulants  787 
 788 
 Catheter related bloodstream infection (CRBSI) 789 
 Evaluating and addressing the barriers to adopting a standardised approach for diagnosing 790 
CRBSI between IF centres 791 
 Role of future technologies (e.g. real time PCR) in diagnosing CRBSI 792 
 Clinical & cost effectiveness of CVC salvage vs. replacement in risk-stratified CRBSI cases 793 
 Consensus on CVC salvage methodology 794 
 Role of antimicrobial locks in primary prophylaxis of CRBSI 795 
  796 
 Intestinal failure associated liver disease 797 
 Novel methods for diagnosis and monitoring (e.g. MR spectroscopy, serum markers). 798 
 Evidence for current preventative strategies (e.g. long-term efficacy & safety of second/third 799 
generation lipids) 800 
 Novel therapeutic targets 801 
 802 
 Non-transplant surgery 803 
 Studies to clarify, compare, and standardize the timing and type of lengthening procedure 804 
805 
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Figure 1. Phases of intestinal failure evolution 806 
 807 
 808 
809 
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